The Effect of a Cancer History on Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention

Takeuchi, Taro; Hikoso, Shungo; Hattori, Satoshi; Kitamura, Tetsuhisa; Nakatani, Daisaku; Mizuno, Hiroya; Okada, Katsuki; Dohi, Tomoharu; Kojima, Takayuki; Kida, Hirota; Sunaga, Akihiro; Oeun, Bolrathanak; Sato, Taiki; Sakata, Yasuhiko; Sato, Hiroshi; Hori, Masatsugu; Komuro, Issei; Sobue, Tomotaka; Sakata, Yasushi

doi:10.1536/ihj.20-452

Cited by 8 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of women in this group of patients with cancer and CHD was higher in most studies [ 3 , 24 , 26 ], but treatment for CHD did not differ significantly between patients with and without cancer [ 3 , 19 , 24 , 26 , 27 ]. However, cancer patients with myocardial infarction were also significantly older and had more concomitant diseases [ 3 , 7 , 19 , 20 , 22 , 24 , 26 , 27 , 28 , 31 , 32 ].…”

Section: Discussionmentioning

confidence: 97%

“…This risk rapidly decreased afterwards but remained elevated 10 years and longer after the cancer diagnosis [ 30 ]. In all of the studies used here, patients with a current or previous cancer diagnosis who received PCI were up to a decade older than the general population with PCI [ 3 , 7 , 19 , 20 , 22 , 24 , 26 , 27 , 28 , 31 , 32 ].…”

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

“…Cancer diagnosis before AMI resulted in higher 30-day mortality, higher 1-year mortality, and worse overall survival [ 26 ]. In the majority of patients, mortality was mainly due to cancer rather than cardiac death [ 24 , 27 ]. Landes et al also showed higher all-cause mortality in cancer patients after PCI.…”

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

“…The question now arises to what extent these findings can be applied to female cancer patients with CHD. The sex ratio in cancer patients with AMI has been inconsistent in various studies [ 3 , 19 , 24 , 26 , 27 ]. In one study that also examined the difference between history of cancer and acute cancer, the proportion of females was higher in the group with history of cancer than in the group with current cancer (43% versus 35%).…”

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

See 3 more Smart Citations

Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Lange

Reinecke

2022

Cancers

View full text Add to dashboard Cite

Cardiovascular disease and cancer remain the leading causes of hospitalization and mortality in high-income countries. Survival after myocardial infarction has improved but there is still a difference in clinical outcome, mortality, and developing heart failure to the disadvantage of women with myocardial infarction. Most major cardiology trials and registries have excluded patients with cancer. As a result, there is only very limited information on the effects of coronary artery disease in cancer patients. In particular, the outcomes in women with cancer and coronary artery disease and its management remain empiric. We reviewed studies of over 27 million patients with coronary artery disease and cancer. Our review focused on the most important types of cancer (breast, colon, lung, prostate) and hematological malignancies with particular attention to sex-specific differences in treatment and prognosis.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

Section: Cancer Patients With Acute Coronary Syndrome (Acs) In Generalmentioning

confidence: 99%

See 2 more Smart Citations

Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Lange

Reinecke

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Cancer patients also had increased risk for recurrent acute coronary syndrome or death (15.2% vs 5.3%; P < 0.001) in a registry study of patients who underwent PCI for acute coronary syndrome ( 194 ). Another registry study from Japan involving 3,499 patients with acute MI treated with PCI showed increased all-cause death in patients with cancer (adjusted HR: 2.43; 95% CI: 1.73-3.42) but no increased incidences of cardiovascular events including acute MI (adjusted HR: 0.71; 95% CI: 0.35-1.42) and stroke (adjusted HR: 1.41; 95% CI: 0.67-2.97) ( 195 ). Despite the increased thrombotic risk in patients with cancer, PCI has still shown the benefit of decreased major adverse cardiovascular events in patients with cancer who had acute coronary syndrome if performed within 72 hours of admission and may be underused in this patient population ( 196 , 197 , 198 ).…”

Section: Thrombotic and Bleeding Risk In Patients With Cancermentioning

confidence: 99%

Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis

Leiva

AbdelHameid

Connors

et al. 2021

JACC: CardioOncology

View full text Add to dashboard Cite

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging evidence suggests common mechanisms between cancer and cardiovascular disease, including atrial fibrillation and atherosclerosis. With advances in cancer therapies, screening, and diagnostics, cancer-specific survival and outcomes have improved. This increase in survival has led to the coincidence of cardiovascular disease, including atrial fibrillation and atherosclerosis, as patients with cancer live longer. Additionally, cancer and cardiovascular disease share several risk factors and underlying pathophysiologic mechanisms, including inflammation, cancer-related factors including treatment effects, and alterations in platelet function. Patients with cancer are at increased risk for bleeding and thrombosis compared with the general population. Although optimal antithrombotic therapy, including agent choice and duration, has been extensively studied in the general population, this area remains understudied in patients with cancer despite their altered thrombotic and bleeding risk. Future investigation, including incorporation of cancer-specific characteristics to traditional thrombotic and bleeding risk scores, clinical trials in the cancer population, and the development of novel antithrombotic and anti-inflammatory strategies on the basis of shared pathophysiologic mechanisms, is warranted to improve outcomes in this patient population.

show abstract

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Leiva

Alam

Bohart

et al. 2023

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion StatementPatients with cancer are at risk of developing cardiovascular disease (CVD) including atherosclerotic heart disease (AHD), valvular heart disease (VHD), and atrial fibrillation (AF). Advances in percutaneous catheter-based treatments, including percutaneous coronary intervention (PCI) for AHD, percutaneous valve replacement or repair for VHD, and ablation and left atrial appendage occlusion devices (LAAODs) for AF, have provided patients with CVD significant benefit in the recent decades. However, trials and registries investigating outcomes of these procedures often exclude patients with cancer. As a result, patients with cancer are less likely to undergo these therapies despite their benefits. Despite the inclusion of cancer patients in randomized clinical trial data, studies suggest that cancer patients derive similar benefits of percutaneous therapies for CVD compared with patients without cancer. Therefore, percutaneous interventions for CVD should not be withheld in patients with cancer, as they may still benefit from these procedures.

show abstract

The Effect of a Cancer History on Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention

Cited by 8 publications

References 34 publications

Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences

Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis

Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population

Contact Info

Product

Resources

About